Neurovance, Inc.: Series A $7M

Posted in I - Series A, Q - 4Q12, R - NORTH EAST, X - ADHD, X - CNS, XX - MA

Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP [...]

Sequent Medical, Inc.: Series C $26M

Posted in I - Series C, Q - 1Q12, R - WEST, X - CNS, X - Device (Aneurysm), XX - CA

Sequent Medical (Aliso Viejo, CA) a commercial-stage medical device company focused on endovascular embolic coils devices for ruptured and non-ruptured intracranial aneurysms, closed a $26M Series C financing. Participants include Delphi Ventures, Versant Ventures, US Venture Partners and Domain Associates. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

NeuroPhage Pharmaceuticals, Inc.: Series B $9M

Posted in I - Series B, Q - 1Q12, R - NORTH EAST, X - Alzheimer's, X - CNS, X - Parkinson's, XX - MA

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on small molecules for protein aggregation diseases such as Alzheimer’ and Parkinson’s disease, closed a $9M Series B financing, bringing the total round to $21.4M. Participants include Merieux Developpement and Shire.

MedGenesis Therapeutix, Inc.: Series C $5M

Posted in I - Series C, Q - 1Q12, R - INTERNATIONAL, X - CNS, X - Epilepsy, X - Hearing Loss, X - Oncology, X - Parkinson's

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

MedGenesis Therapeutix, Inc.: Series C $5M

Posted in I - Series C, Q - 1Q12, R - INTERNATIONAL, X - CNS, X - Epilepsy, X - Hearing Loss, X - Parkinson's

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

Probiodrug, AG: Series C $20M

Posted in I - Series C, Q - 1Q12, R - INTERNATIONAL, X - Alzheimer's, X - CNS, X - Immunology, X - Inflammation, X - Neuro Degenerative

Probiodrug (Germany) a clinical-stage biopharmaceutical company focused enzyme inhibitors for Alzheimer’s and inflammatory disease, closed a $20M Series C financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Sciences Partners, Biogen Idec New Ventures, TVM Capital, HBM BioVentures, Goodvent and Wellington Management Company.

Sage Therapeutics, Inc.: Series A $35M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - CNS, X - Depression, X - Pain, X - Schizophrenia, XX - MA

Sage Therapeutics (Watertown, MA) a development-stage pharmaceutical company focused on modulators of neuronal activity for schizophrenia, depression, pain and traumatic brain injury, closed a $35M Series A financing. Participants include Third Rock Ventures.

CeNeRx BioPharma, Inc.: Series D $4.6M

Posted in I - Series C, Q - 4Q11, R - SOUTH EAST, X - Anxiety, X - CNS, X - Depression, XX - NC

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, depression and anxiety, closed a $4.6M Series D financing. Participants include Aisling Capital, L Capital Partners, Perseus Soros Biopharmaceutical Fund, Omega Funds and Pappas Ventures.

PharmacoFore, Inc.: Series A $10M

Posted in I - Series A, Q - 4Q11, R - WEST, X - Addiction, X - CNS, X - Neurology, X - Pain, XX - CA

PharmacoFore (San Carlos, CA) a clinical-stage biopharmaceutical company focused on improvement of existing drugs preventing misuse, abuse, and overdose of prescription medications for pain, closed a $10M Series A financing. Participants include Founders Fund.

MSI Methylation Sciences, Inc.: Series A $18.2M

Posted in I - Series A, Q - 3Q11, R - INTERNATIONAL, X - CNS, X - Depression

MSI Methylation Sciences (Canada) a preclinical-stage pharmaceutical company focused on depression, closed a $18.2M Series A financing. Participants include Inventages, GrowthWorks and BC Advantage Funds.

Prexa Pharmaceuticals, Inc.: Series B $7M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - CNS, XX - MA

Prexa Pharmaceuticals (Boston, MA) a preclinical-stage biotechnology company focused on ADHD, depression, Parkinson’s and other CNS related diseases, closed a $7.0M Series B financing. Participants include Advent Healthcare Ventures and Shire.

Naurex, Inc.: Series A $18M

Posted in I - Series A, Q - 2Q11, R - MID WEST, X - CNS, X - Depression, XX - IL

Naurex (Evanston, IL) a clinical-stage pharmaceutical company focused on depression and other CNS-related disorders, closed a $18M Series A financing. Participants include Adams Street Partners, Latterell Venture Partners, Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire.

Delenex Therapeutics, AG: Series A $19.3M

Posted in I - Series A, Q - 2Q11, R - INTERNATIONAL, X - CNS, X - Dermatology

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

« Previous Entries Next Page »

to top of page...